london euretina

Instructional Courses

Buy courses during registration or login to your account
if you have already registered

  • Sunday 20 September
    09:00-10:30

  • IC 39
  • wetlab prerequisite
    Pharmacokinetics & Pharmacodynamics of Intravitreal Drugs in Vitreoretinal Diseases

    C. Meyer SWITZERLAND

    Abstract    Schedule



  • Chairperson: C. H. Meyer SWITZERLAND, E. Stefansson ICELAND


    Cost: €25

    • 09.00
    • E. Stefansson ICELAND

      Diffusion characteristics of vitreous humour.



    • 09.10
    • A. Loewenstein ISRAEL

      Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.



    • 09.20
    • S. Fauser GERMANY

      Vascular endothelial growth factor suppression under ranibizumab



    • 09.30
    • C. H. Meyer SWITZERLAND

      Vascular endothelial growth factor suppression under aflibercept



    • 09.40
    • P. Stalmans BELGIUM

      Vitreous levels of active ocriplasmin following intravitreal injection



    • 09.50
    • B. Kuppermann USA

      Pharmacokinetiks of sustained-release dexamethasone implants in vitrectomized and non-vitrectomized eyes



    • 10.00
    • F. Behar-Cohen SWITZERLAND

      Potential of particulate system for the intravitreal injection of therapeutic molecules.



    • 10.10
    • W. Mieler USA

      Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye


    • 10.20

    • Discussion

    • 10.30

    • End of course


  • Abstract:
    Numerous drugs are frequently injected into the vitreous cavity, for a faster and longer and better efficacy. The course will highlight the effect of currently used intravitreally injected drugs, discuss their pharmacokinetic half-life and biological activity, and discuss their specific biological responds (pharmacodynamics) will be presented. Currently used drugs and sustain and novel drug concepts with prolonged duration will be presented.

  • IC 40
  • wetlab prerequisite
    Steroids in Retinal Therapy

    A.   Augustin GERMANY

    Abstract    Schedule

  • Course

    Organiser: A. Augustin GERMANY


    Cost: €25

    • 09.00
    • B. Kupperman USA

      Steroids for the treatment of retinal diseases: Basic Research and Devices



    • 09.15
    • F. Boscia ITALY

      Steroids for the treatment of DME



    • 09.30
    • A. Loewenstein ISRAEL

      Steroids for the treatment of uveitis and other vascular diseases



    • 09.45
    • S. Rizzo ITALY

      Steroid as an important adjunct before, during and after vitreoretinal surgery



    • 10.00
    • A. Augustin GERMANY

      Combination of Steroids with drugs and/or laser for the treatment of Macular edema albertaugustin@googlemail.com;




    • 10.15

    • Discussion

    • 10.30

    • End of course



  • Title:: Steroids in retinal therapy

    Chairperson - Prof. Dr. Albert J. Augustin

    Inflammatory reactions are important pathways contributing to the tissue damage in many retinal disorders such as retinal vein occlusions, diabetic retinopathy and posterior uveitis. Thus, there is a rationale to antagonize those reactions by potent anti-inflammatory drugs such as cortiCost: eroids. New drugs and/or new indications have been introduced in our field. This course we provide the audience with newest data on basic research results from both, pathogenesis and therapeutic strategies. In addition, the treatment of chronic and non-chronic DME, uveitis and vascular diseases will be discussed in detail. In certain diseases steroids are a valuable adjunct when surgery is performed. We will therefore provide the newest results on this topic. Finally, combination strategies consisting of Steroids with drugs and/or laser for the treatment of macular edema from various origins will be discussed.

  • IC 41
  • wetlab prerequisite
    Macular Dystrophies

    G. Querques ITALY E. Souied FRANCE

    Abstract    Schedule

  • Course Organisers: G. Querques ITALY, E. Souied FRANCE


    Cost: €25

    • 09.00
    • G. Querques ITALY

      Best Disease
      giuseppe.querques@hotmail.it



    • 09.15
    • C. J. Boon NETHERLANDS

      Pattern Dystrophies
      c.j.f.boon@lumc.nl



    • 09.30
    • E. Souied FRANCE

      Stargardt disease and FFM
      eric.souied@chicreteil.fr



    • 09.45
    • C.I. Hyong NETHERLANDS

      Macular dystrophies mimicking AMD
      carel.hoyng@radboudumc.nl



    • 10.00
    • B. Leroy UK

      Cone Dystrophies
      bart.leroy@ugent.be



    • 10.15
    • I. Audo FRANCE

      X-linked retinoschisis
      isabelle.audo@inserm.fr



    • 10.30

    • End of course



  • Title:: Macular Dystrophies




    Course Leader:
    Giuseppe Querques, Eric H Souied

    Audience Level: Retina specialists & Comprehensive ophthalmologists/ Intermediate to Advanced

    Format Options:
    Hands-on skills transfer courses

    Abstract and outline

    Background: The intricate and complex anatomy and physiology of the retina explain why many genes are involved in the development of the macula. Modern genetics has helped to identify a few genetic defects implicated in various macular dystrophies. However, different genetic disorders may show overlapping phenotypes and, in the end stages, many diseases can appear identical. Moreover, the same genetic abnormality may show different phenotypes (intra-family and inter-families variability). Therefore, until more information is available as to which genetic problem leads to a specific macular dystrophy, classification of the various disorders will be challenging.
    Aim: This course will deal with the clinical characteristics and ancillary tests on which ophthalmologists must rely upon to determine a specific macular dystrophy.




    Course Description: Description of the clinical characteristics and ancillary tests on which ophthalmologists must rely upon to determine a specific macular dystrophy.


    Course Objectives:
    To show the clinical characteristics and ancillary tests on which ophthalmologists must rely to determine a specific macular dystrophy.
    To differentiate clinically among the disorders and give the patient the best genetic counseling and advice on visual prognosis.

    Conclusion: At the conclusion of this course the attendee will be able to differentiate clinically among the disorders and give the patient the best genetic counselling and advice on visual prognosis.

  • IC 42
  • wetlab prerequisite
    Differential Diagnosis of Intraocular Tumors & Pseudo-Tumors

    L.   Zografos SWITZERLAND

    Abstract    Schedule



  • Chairperson: L. Zografos SWITZERLAND


    Cost: €25

    • 09.00
    • L. Desjardins FRANCE

      Differential diagnosis of small pigmented choroidal tumors




    • 09.15
    • M. S. Sagoo UK

      Differential diagnosis of un-pigmented choroidal tumors



    • 09.30
    • N.E. Bechrakis AUSTRIA

      Differential diagnosis of choroidal tumors in opaque media



    • 09.45
    • F. Munier SWITZERLAND

      Differential diagnosis of intraocular tumors in pediatric population



    • 10.00
    • A. Schalenbourg SWITZERLAND

      Differential diagnosis of intra-ocular vascular tumors



    • 10.15
    • L. Zografos SWITZERLAND

      Differential diagnosis of tumors and pseudo-tumors of the optic disk




    • 10.30

    • End of course


  • 0

  • Sunday 20 September
    11:00-13:00

  • IC 44
  • wetlab prerequisite
    New Frontiers in the Vitreoretinal Interface

    D.   Pelayes ARGENTINA

    Abstract    Schedule

  • Coordinator: D. E. Pelayes ARGENTINA


    Cost: €25

    • 11.00
    • D. E.Pelayes  ARGENTINA

      Swep Source OCT in VR Interface



    • 11.10
    • R.Cano  MEXICO

      Selection of staining for macular surgery



    • 11.20
    • A.Nikolakopoulos  GREECE

      Current pucker and traction macular surgery in VR interface. New techniques using wide angle observation systems



    • 11.30
    • A.Gaudric  FRANCE

      Early vitreo-macular traction: Do we know the natural history?



    • 11.40
    • T.Wolfensberger  SWITZERLAND

      Pharmacological and surgical combination in vitreoretinal interface



    • 11.50
    • C.Forlini  Italy

      Vitreoretinal Interface and Ocular Trauma



    • 12.00
    • F.Graue  MEXICO

      The importance of internal limiting membrane and external limiting membrane



    • 12.10
    • M.Nehemy  BRAZIL

      Surgical techniques for special cases of macular disease



    • 12.20
    • B.Corcóstegui  SPAIN

      Myopic hole interface




    • 12.30
    • Y.LeMer  FRANCE

      Small macular holes: do we still need surgery?




    • 12.40
    • D.E.Pelayes  ARGENTINA





    • 12.50

    • Discussion/ Questions

    • 13.00

    • End of course



  • Title:: New Frontiers in the Vitreoretinal Interface

    Coordinator: David Pelayes
    Educational Level:
    Intermediate

    Target Audience:Subspecialist

    Synopsis
    Using intraoperative videotapes and case presentations, a panel of internationally recognized experts will demonstrate their approach to various types of diseases involving the vitreoretinal interface. Including: Macular Hole, Macular Pucker, Traumatic Macular Hole, Diabetic Traccional Macular Edema, Myopic Macular Hole and others.
    Clinical evolution and diagnosis options will also be analyzed along with a review of the different management options employed by the panelists.

    Objective
    To familiarize participants with specific treatment recommendations and the management of unusual clinical and surgical vireo retinal diseases.






  • Sunday 20 September
    11:00-12:30

  • IC 45
  • wetlab prerequisite
    Age Related Macular Degeneration: Beyond Anti VEGF Therapy

    T. J. Wolfensberger SWITZERLAND

    Abstract    Schedule



  • Course Directors: A. Ambresin SWITZERLAND, I. Mantel SWITZERLAND, T. J. Wolfensberger SWITZERLAND


    Cost: €25

    • 11.00
    • I. Mantel SWITZERLAND

      Refractory AMD and its differential diagnosis



    • 11.12
    • F. Behar-Cohen SWITZERLAND

      AntiVEGF: The other mecansims of action



    • 11.24
    • S. Zweifel SWITZERLAND

      What is the evidence regarding cataract surgery in patients with AMD?



    • 11.36
    • E. Sharkawi SWITZERLAND

      Consequences of repetitive injections on intraocular pressure: Practical tips



    • 11.48
    • J. Pournaras SWITZERLAND

      Mangement of large submacular haemorrhages in AMD: Inject or operate?



    • 12.00
    • T. J. Wolfensberger SWITZERLAND

      AMD and vitreomacular traction: Vitrectomy or ocriplasmin?



    • 12.12
    • A. Ambresin SWITZERLAND

      Is there still a role for photodynamic therapy in 2015?



    • 12.24

    • Discussion

    • 12.30

    • End of course



  • Title:: Age Related Macular Degeneration : beyond anti VEGF therapy

    Course Leaders: Aude Ambresin, MD, Irmela Mantel, MD, Thomas J. Wolfensberger, MD


    Audience Level: Retina specialists/Comprehensive ophthalmologists/ Intermediate / Advanced

    Format Options:
    Didactic presentations with scheduled questions and answers and case presentations managed by the course director

    Abstract and outline

    Anti-VEGF treatment is the mainstay of AMD treatment. However, in several patients this therapy will not suffice on its own to manage all stages of the disease completely. This complex group of patients may include cases where AMD has become refractory to anti-VEGF treatment and other drugs and lasers such as PDT may in some cases have to be used to complement the pharmacological action. In other cases the questions will be focusing on when should we operate the cataract in AMD patients and will the extraction affect the evolution of AMD positively or negatively, and how should we manage increased intraocular pressure following repetitive anti-VEGF injections? How should we finally manage cases where there are mechanical constraints, which hinder anti-VEGF therapy response such as vitreomacular traction or end stage complications of AMD with large submacular hemorrhages? This course will answer these questions and provide a roadmap to manage complex AMD cases comprehensively.

    Readings:
    Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, Russell SR, Boldt HC, Sohn EH Ophthalmology. 2013 Oct;120(10):2029-34

    The impact of cataract surgery on AMD development and progression.
    Qian CX, Young LH. Semin Ophthalmol. 2014 Sep-Nov;29(5-6):301-11

    Predictors of sustained intraocular pressure elevation in eyes receiving intravitreal anti-vascular endothelial growth factor therapy. Yannuzzi NA, Patel SN, Bhavsar KV, Sugiguchi F, Freund KB.
    Am J Ophthalmol. 2014 Aug;158(2):319-327

    Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Treumer F, Roider J, Hillenkamp J. Br J Ophthalmol. 2012 May;96(5):708-13

    Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Cuilla TA, Ying GS, Maguire MG, Martin DF, Jaffe GJ, Grunwald JE, Daniel E, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Ophthalmology. 2015 Mar 28. pii: S0161-6420



    Course Description:
    At the end of this course the participants will have grasped several differents treatment options which complement the anti-VEGF therapies in the comprehensive management of AMD patients

    Conclusion:
    At the end of this course the participants will be able to comprehensively manage AMD patients


  • IC 46
  • wetlab prerequisite
    Update in Ocular Oncology 2015

    A.   Joussen GERMANY

    Abstract    Schedule

  • Course

    Organiser: A. Joussen GERMANY,

    • 11.00
    • S. Ochsenreither GERMANY

      Choroidal metastesis – in the view of the oncologist



    • 11.10
    • M. Rehak GERMANY

      Vascular tumours and vascular abnormalities - treatment challenges



    • 11.20
    • A. Riechardt GERMANY

      Are OCT, FAG and autofluorescence sufficient for differential diagnosis of small choroidal lesions?


    •  
    • 11.30
    • H. Heimann UK

      Should every lesion be biopsied?



    • 11.40
    • N. Bechrakis AUSTRIA

      What type of radiation is the best for the tumour?



    • 11.50
    • S. Leyvraz SWITZERLAND

      Help in sight for metastatic choroidal melanoma? 



    • 12.00
    • I. Seibel GERMANY

      Radiation retinopathy – update



    • 12.10
    • A. Joussen GERMANY

      Surgery after irradiation of large ocular tumours - a necessity or possible alternatives?



    • 12.20

    • Discussion

    • 12.30

    • End of course


  • Update in Ocular Oncology 2015

    This course gives an overview on current clinical treatments in ocular oncology, detailing different diagnostic approaches and radiation treatments. Pathology of Radiation retinopathy will be detailed as well as potential ways of avoidance and treatment.
    For choroidal melanoma, surgical prevention of toxic tumor syndrome will be discussed. Furthermore the latest news on treatment approaches for metastatic disease will be presented.
    Finally the view of the oncologist on choroidal metastesis – origin, disease stages, treatments – will give insight into oncology 2015.
    Last but not least we will discuss benign tumors and vascular abnormalitis.
    Taken together this course will give an up to date overview on the hot topics in ocular oncology.

EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy